SCHEMBL19853843

SCHEMBL19853843

C=C(CO)C(=O)OCCOc1ccc(-c2ccc(-c3ccc(C4CCC(CCCCC)CC4)cc3)cc2)cc1OCCOC(=O)C(=C)CO

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.36
PPARG P37231 6/20 0.35
PTPN11 Q06124 3/20 0.35
FPR2 P25090 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
PTPN1 P18031 1/20 0.34
PTPN6 P29350 1/20 0.34
DGAT1 O75907 2/20 0.34
PDE4A P27815 2/20 0.33
PDE4B Q07343 2/20 0.33
PDE4C Q08493 2/20 0.33
PDE4D Q08499 2/20 0.33
PPARA Q07869 2/20 0.33
RAB9A P51151 1/20 0.33
P2RY14 Q15391 1/20 0.32
SOAT1 P35610 1/20 0.32
MCHR1 Q99705 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19855086 1.00 CYP2C9 (0.36) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL19853858 0.99 PTPN11 (0.37) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL20407651 0.97 FPR2 (0.35) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL19853855 0.94 PDE4A (0.39) CYP2C9PPARGALDH1A1LMNAMAPT
SCHEMBL19853851 0.93 FFAR4 (0.33) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL19722369 0.93 RARB (0.36) CYP2C9PPARGPTPN11ALDH1A1LMNA
SCHEMBL19853861 0.93 PTPN11 (0.33) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL19853846 0.93 CYP2C9 (0.37) CYP2C9PPARGPTPN11FPR2ALDH1A1
SCHEMBL19721859 0.92 S1PR1 (0.39) CYP2C9PPARGPTPN11ALDH1A1LMNA
SCHEMBL20313592 0.92 CYP2C9 (0.36) CYP2C9PPARGPTPN11FPR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210214615-A1 LIQUID CRYSTAL DISPLAY DEVICE AND DISPLAY UNIT JNC CORPORATION (JP) 2021-07-15 US disclosed
EP-3351525-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY ELEMENT JNC Corporation (JP) 2018-07-25 EP disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 US disclosed
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC CORPORATION (JP) 2018-06-28 US disclosed
WO-2018025974-A1 LIQUID-CRYSTAL DISPLAY ELEMENT AND DISPLAY DEVICE JNC株式会社 2018-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180179443-A1 POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE C1S, CCND1, C5 CYP2C9 3375/4885PPARG 2686/4885PTPN11 3649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.